Mr. Robert Leroy Hamlin, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 155 Boulder Hill Pass, Montgomery, IL 60538 Phone: 630-844-3001 Fax: 630-552-1052 |
Brenda Joi Barnwell, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 126 Boulder Hill Pass, Montgomery, IL 60538 Phone: 630-892-6213 |
Erica Lopez-linton, MSW, LSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1935 Candlelight Cir, Montgomery, IL 60538 Phone: 630-885-1671 |
Deborah M Aimone, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1813 Waverly Way, Montgomery, IL 60538 Phone: 630-618-6943 |
Mr. Charles K Barr Jr., L.C.S.W Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 115 Boulder Hill Pass, Montgomery, IL 60538 Phone: 630-844-3001 |
Beth Seeley Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 33 Scarsdale Rd, Montgomery, IL 60538 Phone: 181-592-2641 |
Melissa Novacek Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1703 Marilyn Dr, Montgomery, IL 60538 Phone: 630-730-2016 |
Michelle R Evans, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 155 Boulder Hill Pass, Montgomery, IL 60538 Phone: 630-844-3001 |
Sandra Sarmiento Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2068 Kate Dr, Montgomery, IL 60538 Phone: 630-450-3876 |
Ms. Amanda S Perkins, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 78 Springdale Rd, Montgomery, IL 60538 Phone: 331-725-0067 |
News Archive
Some people living with HIV/AIDS in Zambia are abandoning their antiretroviral drug regimens for ineffective drugs that in recent weeks have been promoted in the media as cures for the disease, the Network of Zambian People Living with HIV and AIDS said on Monday, AFP/Independent Online reports.
St. Jude Medical, Inc., a global medical device company, today announced that it has met a stopping rule in its RESPECT clinical trial - triggered by reaching the protocol-required number of primary events in the trial, defined as stroke and all-cause mortality - and is closing patient enrollment.
"Senate Finance Chairman Max Baucus, D-Mont., said Tuesday he expects Senate health-care legislation will include provisions encouraging doctors to compare drugs and therapies for their effectiveness," Dow Jones Newswires reports.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
› Verified 9 days ago